Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks
NCT ID: NCT02090465
Last Updated: 2019-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
840 participants
OBSERVATIONAL
2013-07-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
all eligible patients
Treatment with Picato according to Summary of Product Characteristics (SmPC)
Ingenol Mebutate
No intervention: observation of routine use of Picato®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ingenol Mebutate
No intervention: observation of routine use of Picato®
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any other specific local treatment of actinic keratoses on the area planned for treatment during the last 8 weeks
* Melanoma, squamous cell carcinoma or spinalioma on the area planned for treatment
* Open wounds on the area planned for treatment
* Contraindications according to prescribing information
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LEO Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas Diepgen, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
University Hospital Heidelberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Heidelberg/Klinische Sozialmedizin
Heidelberg, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DE-Picato NIS-2013
Identifier Type: -
Identifier Source: org_study_id